Undisclosed anti-c-MET/PD-L1 antibody / Sorrento - LARVOL DELTA

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (GlobeNewswire) - “Sorrento Therapeutics...announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference...The conference is being held virtually on September 13-15, 2021…Abivertinib: Phase 3 topline data in NSCLC available Q4 2021…IND for Phase 2 in Prostate Cancer to be filed Q4 2021. PD-L1 antibody: In Phase 3 for SCLC and NDA submission in China for recurrent or metastatic cervical cancer. CD38 ADC: In Phase 1 for Amyloidosis and Multiple Myeloma. CD38 DAR-T: In Phase 1 for Relapsed and Refractory Multiple Myeloma. CD47 antibody: In Phase 1 in solid tumors. SOFUSA: Lymphatic delivery of Enbrel in Phase 1b in refractory rheumatoid arthritis patients.”

Clinical data • IND • P3 data: top line • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor